GLP1R and myotonic dystrophy type 2: Bizino et al. pointed out, with the employment of cardiac magnetic resonance (CMR) in DM2 patients treated with liraglutide, a reduction in the LV filling pressure with a non-significant reduction in the systolic function after 26 weeks of treatment [56], and the same results were obtained by Yari et al. [57] The meta-analysis by Zhang et al. in a larger sample of 4790 subjects, highlights an increase in LVEF and a reduction in LVESV and E/e’ with GLP1-RAs compared to the placebo [20].